Katherine L. B. Borden

In acute myeloid leukemia, Ezrin binds eIF4E and anchors active ribosomes in pseudopods for local translation of CD44 and hyaluronan pathway proteins; eIF4E loss impairs mouse engraftment.

The paper presents a chemical-genetic interaction matrix derived from CRISPR/Cas9 screens, revealing drug mechanisms and genetic architecture in human cells.

The paper shows eIF4E and NCBP2 have distinct roles in nuclear mRNA processing, influencing different transcript populations and outcomes.

This study shows that disrupting the interaction between HoxA9 and eIF4E delays AML onset and reduces disease penetrance, suggesting eIF4E as a therapeutic target in HoxA9-driven leukemia.